IP Library › Granted Patent US 12,209,286
Granted Patent B2
US 12,209,286 · App. 17/579,355 · Granted Jan 28, 2025

Methods of diagnosing, determining the progression of, and treating a prostate cancer

Inventors: Doug Brooks (North Cheltenham, AU); Emma Parkinson-Lawrence (Morphettville, AU); Ian R. D. Johnson (Littlehampton, AU); Lisa Butler (Paradise, AU)
Assignee: UNIVERSITY OF SOUTH AUSTRALIA
C12Q1/6886G01N33/57434A61N5/10C07K14/4702C07K14/70571C07K16/18C07K16/286C07K16/3069C07K2317/34C12Q2600/106C12Q2600/112C12Q2600/118C12Q2600/158G01N2333/4703G01N2333/82G01N2333/96455G01N2800/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,286
App. No.
17/579,355
Granted
Jan 28, 2025
Kind
B2
Abstract

Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.

Claims (23)

1. A method of diagnosing and treating a prostate cancer in a subject, the method comprising:

detecting APPL1 and SDC1 in a sample obtained from the subject;

determining the ratio of the level of APPL1 to the level of SDC1 in the sample;

comparing the ratio of the level of APPL1 to the level of SDC1 in the sample to the ratio of the level of APPL1 to the level of SDC1 in a non-malignant tissue to obtain an indication of prostate cancer in the subject, wherein an increased ratio of APPL1 to SDC1 in the sample as compared to the non-malignant tissue is indicative of prostate cancer in the subject; and

administering to the subject having prostate cancer an effective amount of a therapeutic agent.

2. The method according to claim 1 , wherein the method further comprises detecting one or more of an early endosomal marker, a late endosomal marker, a marker associated with endosomal biogenesis, a marker associated with endosomal trafficking and a marker associated with endosomal recycling.

3. The method according to claim 2 , wherein the further marker is selected from one or more of SORT1, M6PR (CD-MPR), IGF2R (CI-MPR), PDC6IP (ALIX), and MYO1B (Myosin 1B).

4. The method of claim 1 , wherein the detecting and/or determining steps involve immunological methods, including ELISA, staining and visualization with an antibody, immunohistochemistry, and/or flow cytometric detection.

5. A method of diagnosing and treating a prostate cancer in a subject, the method comprising:

detecting SDC1 and SORT1 in a sample obtained from the subject;

determining the ratio of the level of SDC1 to the level of SORT1 in the sample;

comparing the ratio of the level of SDC1 to the level of SORT1 in the sample to the ratio of the level of SDC1 to the level of SORT1 in a non-malignant tissue to obtain an indication of prostate cancer in the subject, wherein an increased ratio of SDC1 to SORT1 in the sample as compared to the non-malignant tissue is indicative of prostate cancer in the subject; and

administering to the subject having prostate cancer an effective amount of a therapeutic agent.

6. The method according to claim 5 , wherein the method further comprises detecting one or more of an early endosomal marker, a late endosomal marker, a marker associated with endosomal biogenesis, a marker associated with endosomal trafficking and a marker associated with endosomal recycling.

7. The method according to claim 6 , wherein the further marker is selected from one or more of APPL1, M6PR (CD-MPR), IGF2R (CI-MPR), PDC6IP (ALIX), and MYO1B (Myosin 1B).

8. The method according to claim 5 , wherein the increased ratio of SDC1 to SORT1 is indicative of an increased relapse rate and/or decreased survival rate.

9. A method of determining the progression of and treating prostate cancer in a subject, the method comprising:

detecting APPL1 and SDC1 in a sample obtained from the subject;

determining the ratio of the level of APPL1 to the level of SDC1 in the sample;

comparing the ratio of the level of APPL1 to the level of SDC1 in the sample to the ratio of the level of APPL1 to the level of SDC1 in a non-malignant tissue to obtain an indication of prostate cancer in the subject, wherein an amount of increase in the ratio of APPL1 to SDC1 in the sample is an indication of the progression of prostate cancer in the subject; and

administering to the subject having prostate cancer an effective amount of a therapeutic agent in response to the indication of progression.

10. The method according to claim 9 , wherein the method further comprises detecting one or more of an early endosomal marker, a late endosomal marker, a marker associated with endosomal biogenesis, a marker associated with endosomal trafficking and a marker associated with endosomal recycling.

11. The method according to claim 10 , wherein the further marker is selected from one or more of SORT1, M6PR (CD-MPR), IGF2R (CI-MPR), PDC6IP (ALIX), and MYO1B (Myosin 1B).

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Jun 2, 2026
From: UNIVERSITY OF SOUTH AUSTRALIA
To: ADELAIDE UNIVERSITY
Reel/Frame 075695/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2022
From: BROOKS, DOUG; PARKINSON-LAWRENCE, EMMA; JOHNSON, IAN R.D.; BUTLER, LISA
To: UNIVERSITY OF SOUTH AUSTRALIA
Reel/Frame 058716/0583 →
Priority Claims (1)
AU 2013902141 · Jun 13, 2013 · national
Continuity (3)
Continuation 15794270 · Jan 23, 2018
Continuation 14897612
Related Publication 20220154292A1 · May 19, 2022
References Cited (37)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5639641A · Pedersen et al. · 1997 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
WO 9222653A1 · 1992 [cited by applicant]
Mitsuuchi et al, 1999. Oncogene. 18: 4891-4898. [cited by examiner]
Bae et al, 2011. Br J Haematol. 155(3): 349-361. [cited by examiner]
Benjamini et al, 1991. Immunology: A Short Course, 2nd edition, p. 40 only. [cited by examiner]
Kohler, et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, vol. 256, pp. 495-497,1975. [cited by applicant]
Kozbor, et al., “Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas”, J. Immunol. Methods, vol. 81, pp. 31-42, 1985. [cited by applicant]
Cote, et al., “Generation of human monoclonal antibodies reactive with cellular antigens”, Proc. Natl. Acad. Sci., vol. 80, pp. 2026-2030, 1983. [cited by applicant]
Cole, et al., “Human monoclonal antibodies”, Mol. Cell Biol., vol. 62, pp. 109-120, 1984. [cited by applicant]
Gu, et al., “Construction and expression of mouse-human chimeric antibody SZ-51 specific for activated platelet P-selectin”, Thrombosis and Haemostasis, vol. 77(4), pp. 755-759, 1997. [cited by applicant]
Morrison, et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains”, Proc. Natl. Acad. Sci, vol. 81, pp. 6851-6855, 1984. [cited by applicant]
Neuberger, et al., “Recombinant antibodies possessing novel effector functions”, Nature, vol. 312, pp. 604-608, 1984. [cited by applicant]
Takeda, et al., “Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences”, Nature, vol. 314, pp. 452-454, 1985. [cited by applicant]
I. Johnson et al., “Altered Endosome Biogenesis in Prostate Cancer,” Colloquia Abstract, ComBio2012, COL-03-01, Sep. 23-27, 2012, pp. 92. [cited by applicant]
Paul Mitchell et al., “Can urinary exosomes act as treatment response markers in prostate cancer?” Journal of Translational Medicine 2009, vol. 7, No. 4, pp. 1-13. [cited by applicant]
T. Kallunki et al., “Cancer-associated lysosomal changes: friends or foes?” Oncogene (2013) 32, pp. 1995-2004. [cited by applicant]
James P. Cherry et al., “Analysis of Cathepsin D Forms and Their Clinical Implications in Human Prostate Cancer,” The Journal of Urology, vol. 160, pp. 2223-2228, Dec. 1998. [cited by applicant]
Yaron Mosesson et al., “Derailed endocytosis: an emerging feature of cancer,” Nature Reviews: Cancer, vol. 8, Nov. 2008, pp. 835-850. [cited by applicant]
Stephanie Swift et al., “Altered Expression of Neurotensin Receptors Is Associated with the Differentiation State of Prostate Cancer,” Tumor and Stem Cell Biology, Cancer Research 2010, vol. 70, No. 1, pp. 346-356. [cited by applicant]
Ceren G. Korkmaz et al., “Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer,” Oncogene 2005, vol. 24, No. 31, pp. 4934-4945. [cited by applicant]
Nicholas Turner et al., “Fibroblast growth factor signalling: from development to cancer,” Nature Review Cancer Feb. 2010, vol. 10, No. 2, pp. 116-129. [cited by applicant]
Qian et al., “Identification and expression of two new secretory proteins associated with prostate cancer,” Yi Chaun, 2010, vol. 32, No. 3, pp. 235-241. [cited by applicant]
Alicia Llorente et al., “Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells,” Euroepan Journal of Cell Biology 2007, vol. 86, No. 7, pp. 405-415. [cited by applicant]
Johanna Kiviniemi et al., “Altered expression of syndecan-1 in prostate cancer,” APMIS 2004, vol. 112, pp. 89-97, 2004. [cited by applicant]
Binod Kumar et al., “Oxidative Stress is Inherent in Prostate Cancer Cells and is Required for Aggressive Phenotype,” Cancer Research, vol. 68, No. 6, pp. 1777-1785, 2008. [cited by applicant]
Luz Canacho et al., “Acid ceramidase as a therapeutic target in metastatic prostate cancer,” J. Lipid Res. May 2013, vol. 54, No. 5, pp. 1207-1220. [cited by applicant]
Sinha et al., “Plasma Membrane Association of Cathepsin B in Human Prostrate Cancer: Biochemical and Immunogold Electron Microscopic Analysis,” The Prostate, vol. 49, 2001, pp. 172-184. [cited by applicant]
C. Kelly et al., “Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells,” Am J Physiol Lung Cell Mol Physiol, vol. 304, 2013, pp. L371-L382. [cited by applicant]
J. Wisniewski et al., “Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma,” Molecular Systems Biology, vol. 8, No. 611, 2012, pp. 1-12. [cited by applicant]
M. Jovic et al., “The early endosome: a busy sorting station for proteins at the crossroads,” Histol Histopathol., vol. 25, No. 1, Jan. 2010, pp. 99-112. [cited by applicant]
Hood et al., “Proteomic Analysis of Formalin-Fixed Prostate Cancer Tissue,” Molecular and Cellular Proteomics, vol. 4, 2005, pp. 1741-1753. [cited by applicant]
H. Miyake et al., “Serum Level of Cathepsin B and its Density in Men with Prostate Cancer as Novel Markers of Disease Progression,” Anticancer Research, vol. 24, 2004, pp. 2573-2578. [cited by applicant]
Caspar, et al., “In Vitro Cultivation of Primary Prostate Cancer Cells Alters the Molecular Biomarker Pattern”, In vivo, vol. 30, pp. 573-580, 2016. [cited by applicant]
Ferrara, et al., “Recombinant renewable polyclonal antibodies”, mAbs, vol. 7, No. 1, pp. 32-41, 2015. [cited by applicant]
Yu, et al., “The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer”, Asian Journal of Andrology, vol. 11, pp. 39-48, 2009. [cited by applicant]